The
new trial will be led by the U.K. National Institute for Health and Care
Excellence (NICE) and NHS England and NHS Improvement. It will test a
‘subscription’ style model that pays pharmaceutical companies upfront for access
to drugs based on their usefulness to the NHS.
This
will make it more attractive for companies to invest the estimated £1 billion
it costs to develop a new drug, as they can be reassured they will still be
paid for the drug even though it may be stored for reserves. Currently, drugs
companies are paid by volume of antibiotics sold, while the NHS is trying to
reduce their use to prevent antimicrobial resistance (AMR).
Low
returns on investment in development mean industry is reluctant to invest in
the research and clinical trials necessary to bring new antibiotics to market.
NICE
and NHS England and NHS Improvement are calling for companies to identify
products to be considered for the initial phase of the test. The work will be evaluated from the start and
findings will be shared with the rest of the world so that other healthcare
systems can test similar models.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology
No comments:
Post a Comment
Pharmaceutical Microbiology